letrozole,palbociclib
pfizer,novartis
['paloma-2', 'rova']
paloma-2. no sign os benefit for palbo added to letrozole; have we for years given our patients added toxicity with this costly drug with no survival benefit to show for it? time to reconsider pfs as a primary endpoint and basis for approval? #asco2022
Medical Oncologist